Stay updated on Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page shows a system revision update: added Revision: v3.4.2 and removed Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed from the Study Protocol/Statistical Analysis Plan section.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision: v3.3.4 appears and v3.3.3 is removed. This is a minor metadata update that does not change the study details.SummaryDifference0.0%

- Check83 days agoChange DetectedThe study record now includes a Locations section with multiple site locations (Arizona, California, Colorado, Florida, Maryland, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas, Washington, Alberta, Ontario, Chiba, Tokyo, Lanarkshire). The previous location listings were removed, and the revision is v3.3.3.SummaryDifference1%

- Check112 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.2.0 has been removed. This update pertains to versioning and does not modify any study data, eligibility criteria, or listed locations.SummaryDifference0.0%

Stay in the know with updates to Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.